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Abstract
Aim: To assess serum Hepatocyte Growth Factor (HGF) levels in autistic children with severe gastrointestinal (GI) disease and to test 
the hypothesis that there is a relationship between GI pathology and HGF concentration.
Subjects and Methods: Serum from 29 autistic children with chronic digestive disease (symptoms for a minimum of 6–12 months), 
most with ileo-colonic lymphoid nodular hyperplasia (LNH—markedly enlarged lymphoid nodules) and inflammation of the colorectum, 
small bowel and/or stomach), and 31 controls (11 age matched autistic children with no GI disease, 11 age matched non autistic children 
without GI disease and 9 age matched non autistic children with GI disease) were tested for HGF using ELISAs. HGF concentration of 
autistic children with GI disease was compared to GI disease severity.
Results: Autistic children with GI disease had significantly lower serum levels of HGF compared to controls (autistic without GI 
disease; p = 0.0005, non autistic with no GI disease; p = 0.0001, and non autistic with GI disease; p = 0.001). Collectively, all autistic 
children had significantly lower HGF levels when compared to non autistic children (p  0.0001). We did not find any relationship 
between severity of GI disease and HGF concentration in autistic children with GI disease.
Discussion: These results suggest an association between HGF serum levels and the presence of GI disease in autistic children and 
explain a potential functional connection between the Met gene and autism. The concentration of serum HGF may be a useful biomarker 
for autistic children, especially those with severe GI disease.
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Introduction
Autism is a complex, behaviorally defined neurode-
velopmental disorder characterized by social deficits, 
language impairments, and repetitive behaviors with 
restricted interests. There has been a dramatic increase 
in the diagnosis of autism over the past decade.1,2
The etiology of this complex disease is highly heri-
table, but likely involves environmental factors.58 Twin 
studies demonstrate concordance rates of 82%–92% in 
monozygotic twins and 1%–10% concordance rate in 
dizygotic twins.3 Sibling recurrence risk (6%–8%) is 
35 times the population prevalence.1,4
Genetic analysis suggests that as many as 15 genes 
might  be  involved  in  Autism  Spectrum  Disorders 
(ASD), including variants on chromosomes 2q, 7q, 
15q, and 17q.5–8
Children with autistic spectrum disorders (ASD) 
frequently have accompanying gastrointestinal, immu-
nological, or nonspecific neurological symptoms.9–15
Based  on  neurobiological  findings  and  location 
within a chromosome 7q31 autism candidate gene 
region,62 Campbell et al analyzed the MET receptor 
tyrosine kinase gene in a family based study of autism 
and found a functional variant of MET with autism 
with a calculated relative risk of 2.27.16
MET,  found  originally  to  be  involved  in  cancer 
metastasis,42  facilitates  the  signaling  of  hepatocyte 
growth factor (HGF)/scatter factor and its involvement 
in peripheral organ development and repair,17–19 immune 
function20–22,61 and gastrointestinal repair.18,23,24,59
In  the  central  nervous  system,  MET  contrib-
utes  to  development  of  the  cerebral  cortex25,26  and 
cerebellum.25 Abnormal MET/HGF signaling in the 
cerebral cortex results in atypical interneuron migra-
tion from the ganglionic eminence and reduced inter-
neurons in the frontal and parietal regions of cortex.28,29 
In the cerebellum, aberrant signaling causes decreased 
proliferation  of  granule  cells  and  reduction  in  the 
cerebellar size, particularly in the vermis.25 Both of 
these aberrations are consistent with those observed 
in brains of individuals with autism.26,27,60
Hepatocyte growth factor (HGF), an 82 kDa, 674 
amino acid residue heterodimeric glycoprotein, was 
originally isolated from rat platelets.32,33 This growth 
factor has also been called scatter factor, hepatopoi-
etin A, and mammary growth factor.34 It is one of a 
small family of factors lacking significant homology 
with other known growth factors, but including an 
HGF-like  factor  known  as  macrophage  stimulating 
protein (MSP).35–38 HGF has mitogenic, morphogenic, 
and motogenic effects on hepatocytes, as well as endo-
thelial, mesenchymal and hematopoietic cell types,37,39,40 
and demonstrates noticeable species cross-reactivity.41
Children with autistic spectrum disorders frequently 
have  accompanying  gastrointestinal  symptoms49–51  and 
pathology,  which  includes  inflammation  of  the  GI 
tract53–56  and  autoimmunity  related  to  GI  disease 
severity.57 Because a MET variant exists in the genome 
of  a  significant  number  of  autistic  individuals,  we 
hypothesized that this might result in abnormal lev-
els of serum HGF, particularly those with severe GI 
disease.
Materials and Methods
eLIsA to measure serum hgF (eLIsA 
kit, r&D systems, minneapolis, minn.)
All  reagents  and  specimens  were  equilibrated  to 
room temperature before the assay was performed. 
A 1:51 dilution of the patient samples was prepared 
by mixing 10 µl of the patient’s sera with 0.5 ml of 
Serum Diluent. One hundred microliters of calibra-
tors  (20–200  Eu/ml  antibodies),  positive  and  Nega-
tive control serums, serum diluent alone, and diluted 
patient samples were added to the appropriate microw-
ells of a microculture plate (each well contained affin-
ity  purified  polyclonal  IgG  to  HGF).  Wells  were 
incubated for 60 minutes (±5 min) at room tempera-
ture, then washed 4x with wash buffer. One hundred 
microliters of pre-diluter anti-human IgG conjugated 
with HRP was added to all microwells, incubated for 
30 minutes (±5 min) at room temperature, then wash 
4x  with  wash  buffer.  One  hundred  microliters  of 
enzyme substrate was added to each microwell. After 
approximately 30 minutes at room temperature, the 
reaction was stopped by adding 50 µl of 1 M sulfu-
ric acid, then the wells were read at 405 nm with an 
ELISA reader (BioRad Laboratories, Inc., Hercules, 
CA, USA).
subjects and scoring of severity  
of gI disease
Serum from autistic individuals with GI disease was 
obtained from the Thoughtful House, Austin, Texas.a 
aThe  Thoughtful  House  is  a  comprehensive  treatment  and  research  center, 
specializing in the care of children with neurological disorders, including autism.hgF in autistic children with gastrointestinal disease
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All 29 children in this study with ASD (median age 
6 years; range 2–16; 34 male) with gastrointestinal 
symptoms,  were  investigated  by  ileo-colonoscopy. 
Macroscopic and histological features of the upper 
and lower GI tract were scored. A reproducible scoring 
system, similar to the Crohn’s Disease Endoscopic 
Index of Severity (CDEIS) was developed and used 
to evaluate this unique type of observed enterocolitis 
and severity of disease (particularly inflammation). 
Patients  were  scored  according  to  mild  (1  point), 
moderate (2 points) and marked (3 points) disease 
in  each  area  (upper  and  lower  GI)  and  for  scope 
(macroscopic) and histology of each area. Therefore, 
the maximum score for GI disease was 12 (3 points 
each for upper scope, upper histology, lower scope and 
lower histology). A point system was also developed 
for severity of lymphoid nodular hyperplasia (LNH). 
Patients  were  scored  according  to  mild  (1  point), 
moderate (2 points) and marked (3 points) LNH in 
each area (upper and lower GI) for a maximum of 
6 points. And finally, a point system was also devel-
oped for severity of erythema. Patients were scored 
according to mild (1 point), moderate (2 points) and 
marked (3 points) erythema in each area (upper and 
lower GI) for a maximum of 6 points.
controls
Three control groups (total n = 31) were studied (11 age 
matched autistic children with no GI disease, 11 age 
matched non autistic children without GI disease and 
9 age matched non autistic children with GI disease) 
(mean 71 months), gender (78% male) and diagnosis 
(55% of autistic controls had regressive onset). Serum 
and medical history of controls were obtained from 
the  Autism  Genetic  Resource  Exchange—AGRE.b 
Patients were categorized as having GI disease, not 
having GI disease, or no autistic based on the medical 
history provided by AGRE.
Informed consent
Informed consent was obtained from all patients in 
this study by the Thoughtful House and AGRE, where 
appropriate. IRB of the Thoughtful House approved 
this project.
serums
Experimental (Thoughtful House) and control (AGRE) 
serums were morning draws, then frozen at -70 C 
immediately after collection and cell/serum separation, 
then stored at -70 C until thawed for use in ELISAs.
statistics
Inferential  statistics  were  derived  from  unpaired 
t-test and odds ratios with 95% confidence intervals. 
ANOVA analysis was used to do an analysis of vari-
ance and multiple comparisons.
Results
Serum from 29 autistic children with chronic digestive 
disease  (most  with  ileo-colonic  lymphoid  nodu-
lar  hyperplasia  (LNH)  and  inflammation  of  the 
colorectum, small bowel and/or stomach), and 31 
controls (11 age matched autistic children with no GI 
disease, 11 age matched non autistic children with-
out GI disease and 9 age matched non autistic chil-
dren with GI disease) were tested for HGF using an 
ELISA designed to quantitate HGF levels (described 
above). Each assay was repeated two or more times, 
with multiple wells for each serum in each assay. 
The results of a typical assay are summarized on 
Figures 2 and 3 (Fig. 2—standards; Fig. 3—control/
experimental serums).
Serum  HGF  levels  of  autistic  children  with  GI 
disease were significantly lower than all non autis-
tic controls (p  0.0001) (Table 3), as well each of 
the controls (autistic without GI disease; p = 0.0005, 
non autistic with no GI disease; p = 0.0001, and non 
autistic with GI disease; p = 0.001) (Table 2) (Fig. 1). 
A one-way ANOVA analysis was also performed on 
the four groups (Fig. 4) (F = 14.02; p  0.0001).
HGF  concentration  of  autistic  children  with  GI 
disease was compared to GI disease severity (including 
LNH and erythema). We did not find any significant 
association between HGF levels and severity of the 
GI disease, including severity of LNH and erythema, 
or the presence of autoantibodies (Table 1).
Discussion
Neuropathological findings in autism indicate altered 
organization of  both the cerebral cortex and cerebellum, 
bThe Autism Genetic Resource Exchange (AGRE) is the first collaborative gene 
bank for the study of autism spectrum disorders and one of the world’s largest 
shared resources for the study of autism and related disorders, with a collection 
of over 900 well-characterized multiplex and simplex families made available to 
the greater scientific community. Founded by Cure Autism Now (CAN) in 1997, 
AGRE is currently funded by the National Institute of Mental Health (NIMH) 
and Autism Speaks (AS), which merged with CAN in 2006.russo et al
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Figure 1. The mean +/- sD hgF concentration (pg/ml) of 29 autistic children with chronic digestive disease (most with ileo-colonic lymphoid nodular 
hyperplasia (LNH) and inflammation of the colorectum, small bowel and/or stomach) (A GI), and 30 controls (11 age matched autistic children with no GI 
disease (A no gI), 11 age matched non autistic children without gI disease (nA no gI) and 9 age matched non autistic children with gI disease (nA gI)).
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Figure 2. hgF serum concentration was established for each individual by testing and correlating to known standards of various concentrations of MPO 
(8000 pg/ml–125 pg/ml), as well as negative control (serum diluent alone).hgF in autistic children with gastrointestinal disease
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both of which are disrupted in mice with decreased 
MET signaling activity. There is co-occurrence of 
autism with a number of neurological and cognitive 
disorders, including epilepsy, atypical sleep patterns, 
and mental retardation.30 Together with well known 
dysfunction of cortical information processing, the 
role of MET signaling in interneuron development 
is relevant as a central component of the hypoth-
esized  GABAergic  pathophysiological  changes  in 
autism.31
Although yet to be identified, environmental factors 
likely contribute to the development of autism, herita-
bility studies suggest that the impact of those factors 
probably need to be imposed upon individuals geneti-
cally predisposed to the disorder.
Individuals  with  autism  can  present  complex 
medical profiles, such as gastrointestinal, immune, and 
nonspecific neurological dysfunctions.10–15 In addition 
to brain development, the pleiotropic MET receptor 
tyrosine kinase has specific roles in digestive system 
development  and  repair18,23,24  and  modulation  of 
T cell-activated peripheral monocytes and dendritic 
antigen-presenting cells.20,22
A  polymorphism  in  the  upstream  region  of  the 
hepatocyte growth factor receptor c-Met, that has been 
identified in a study involving 1231 autistic children 
and appropriate controls,16 has the dual consequences 
of a deficiency in c-Met protein level corresponding 
to  reduced  transcription  rate  and  down-regulation 
of  (HGF)  production,  as  c-MET/HGF  signaling  is 
directly related to HGF expression via a positive feed-
back mechanism.43,44 It is thus noteworthy that HGF 
levels have also been shown to be lower in high func-
tioning autistic adult males.45 This raises the question 
of whether biological activity of HGF contributes to 
autism symptomatology.
HGF and c-MET both appear to be pertinent beyond 
brain function and development, since HGF reduces 
inflammation  in  other  tissues46,47  and  can  potently 
suppress  dendritic  cell  functions.48  Thus,  deficien-
cies of both c-MET and HGF lead to conditions that 
would  promote  inflammation  or  oxidative  stress,48 
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Figure 3. serum hgF concentration was measured in a typical eLIsA. Two autistic children with gI disease (A gI), 2 non autistic children with gI disease 
controls (nA gI), 2 autistic children with no gI disease (A no gI) and 2 non autistic children with no gI disease controls (nA no gI) were tested. Four 
replicate samples were tested for each individual. russo et al
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Table 1. relationship between hgF serum concentration and severity of gl disease.  
   HGF (pg/ml)  Mean O.D. 
anti-pR3**
Mean O.D. 
anti-MpO***
Mean O.D. 
AscA****
Diagnosis  
A/RA/Asp/pDD
LnH  eryth  Total Gl  High  
LnH
Low  
LnH
High  
erythema
Low  
erythema
High  
total Gl
Low  
total Gl
AutoAbs  no 
AutoAbs
Autistic children with Gl disease
1 535.97 0.129 0.322 0.162 A 3 1 6 535.97 535.97 535.97 535.97
2 1416.63 0.121 0.286 0.161 RA 1 0 7 1416.63 1416.63 1416.63 1416.63
3 251.31 0.197 0.361 0.253 pDD 2 1 4 251.31 251.31 251.31 251.31
4 1621.23 0.136 0.284 0.19 A 0 0 nA 1621.23 1621.23 1621.23 1621.23
5 847.31 0.099 0.225 0.128 R-Asp 2 1 6 847.31 847.31 847.31 847.31
6 847.31 0.175 0.329 0.169 RA 3 1 nA 847.31 847.31 847.31
7 1256.51 0.576 0.629 0.793 A 4 4 11 1256.51 1256.51 1256.51 1256.51
8 1710.19 0.245 0.416 0.219 R-pDD 1 0 3 1710.19 1710.19 1710.19 1710.19
9 882.90 0.189 0.341 0.169 A 1 2 6 882.90 882.90 882.90 882.90
10 713.88 0.366 0.450 0.556 RA 2 2 6 713.88 713.88 713.88 713.88
11 776.15 0.134 0.274 0.157 RA 2 0 8 776.15 776.15 776.15 776.15
12 1060.81 0.533 0.784 0.696 A 1060.81 1060.81 1060.81
13 580.45 0.544 0.504 0.277 RA 3 0 7 580.45 580.45 580.45 580.45
14 838.42 0.227 0.306 0.169 RA 3 0 5 838.42 838.42 838.42 838.42
15 527.07 0.289 0.327 0.282 RA 6 0 10 527.07 527.07 527.07 527.07
16 1425.53 0.173 0.394 0.195 A 4 0 7 1425.53 1425.53 1425.53 1425.53
17 687.19 0.166 0.313 0.169 RA 3 2 7 687.19 687.19 687.19 687.19
18 1185.35 0.141 0.414 0.169 RA 2 0 3 1185.35 1185.35 1185.35 1185.35
19 624.92 0.482 0.566 0.78 RA 3 2 6 624.92 624.92 624.92 624.92
20 669.40 0.235 0.435 0.29 RA 3 0 6 669.40 669.40 669.40 669.40
21 384.74 0.274 0.506 0.343 R-pDD/nOs 2 1 4 384.74 384.74 384.74 384.74
22 509.28 0.221 0.537 0.249 RA 2 2 7 509.28 509.28 509.28 509.28
23 375.85 0.140 0.356 0.151 RA 2 0 4 375.85 375.85 375.85 375.85
24 453.34 0.196 0.360 0.299 RA 0 2 5 453.34 453.34 453.34 453.34
25 845.97 0.259 0.463 0.248 RA 3 0 4 845.97 845.97 845.97 845.97
26 480.42 0.174 0.457 0.174 A 3 4 6 480.42 480.42 480.42 480.42
27 660.94 0.199 0.503 0.196 RA 3 2 5 660.94 660.94 660.94 660.94
28 800.84 0.443 0.539 0.426 R-pDD 5 0 nA 800.84 800.84 800.84
29 954.28 0.278 0.529 0.228 R-pDD 3 1 8 954.28 954.28 954.28 954.28
Mean 824.97 782.35 870.64 868.46 821.75 805.49 832.73 754.67 861.98
sD 376.09 267.12 472.71 548.78 374.94 311.97 520.38 267.13 424.44
p = 0.5373 p = 0.8690 p = 0.8682 p = 0.4752
hgF concentration of autistic children with gI disease, with (bold) and without Lnh, with (bold) and without erythema, with (bold) and without severe total 
gI disease, and with (bold) and without auto-antibodies (AncA and/or AscA), are compared. Diagnosis of autistic children with gI disease  (A-autistic; 
rA-autistic with regressive onset; PDD-pervasive developmental disorder; UD-undetermined; AsP-aspergers), severity of lymphonodular hyperplasia 
(Lnh), presence and severity of erythema, total gI disease severity, as well as the presence of auto-antibodies (AutoAb) are posted. severity of gI disease 
was scored according to mild (1 point), moderate (2 points) and marked (3 points) disease in each area (upper and lower gI) and for scope (macroscopic) 
and histology of each area. Therefore the maximum score for gI disease would be 12 (3 points each for upper scope, upper histology, lower scope and 
lower histology). A point system was also developed for severity of lymphoid nodular hyperplasia (Lnh). Patients were scored according to mild (1 point), 
moderate (2 points) and marked (3 points) LNH in each area (upper and lower GI) for a maximum of 6 points. And finally, a point system was also 
developed for severity of erythema. Patients were scored according to mild (1 point), moderate (2 points) and marked (3 points) erythema in each area 
(upper and lower gI) for a maximum of 6 points. hgF in autistic children with gastrointestinal disease
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Table 1. relationship between hgF serum concentration and severity of gl disease.  
   HGF (pg/ml)  Mean O.D. 
anti-pR3**
Mean O.D. 
anti-MpO***
Mean O.D. 
AscA****
Diagnosis  
A/RA/Asp/pDD
LnH  eryth  Total Gl  High  
LnH
Low  
LnH
High  
erythema
Low  
erythema
High  
total Gl
Low  
total Gl
AutoAbs  no 
AutoAbs
Autistic children with Gl disease
1 535.97 0.129 0.322 0.162 A 3 1 6 535.97 535.97 535.97 535.97
2 1416.63 0.121 0.286 0.161 RA 1 0 7 1416.63 1416.63 1416.63 1416.63
3 251.31 0.197 0.361 0.253 pDD 2 1 4 251.31 251.31 251.31 251.31
4 1621.23 0.136 0.284 0.19 A 0 0 nA 1621.23 1621.23 1621.23 1621.23
5 847.31 0.099 0.225 0.128 R-Asp 2 1 6 847.31 847.31 847.31 847.31
6 847.31 0.175 0.329 0.169 RA 3 1 nA 847.31 847.31 847.31
7 1256.51 0.576 0.629 0.793 A 4 4 11 1256.51 1256.51 1256.51 1256.51
8 1710.19 0.245 0.416 0.219 R-pDD 1 0 3 1710.19 1710.19 1710.19 1710.19
9 882.90 0.189 0.341 0.169 A 1 2 6 882.90 882.90 882.90 882.90
10 713.88 0.366 0.450 0.556 RA 2 2 6 713.88 713.88 713.88 713.88
11 776.15 0.134 0.274 0.157 RA 2 0 8 776.15 776.15 776.15 776.15
12 1060.81 0.533 0.784 0.696 A 1060.81 1060.81 1060.81
13 580.45 0.544 0.504 0.277 RA 3 0 7 580.45 580.45 580.45 580.45
14 838.42 0.227 0.306 0.169 RA 3 0 5 838.42 838.42 838.42 838.42
15 527.07 0.289 0.327 0.282 RA 6 0 10 527.07 527.07 527.07 527.07
16 1425.53 0.173 0.394 0.195 A 4 0 7 1425.53 1425.53 1425.53 1425.53
17 687.19 0.166 0.313 0.169 RA 3 2 7 687.19 687.19 687.19 687.19
18 1185.35 0.141 0.414 0.169 RA 2 0 3 1185.35 1185.35 1185.35 1185.35
19 624.92 0.482 0.566 0.78 RA 3 2 6 624.92 624.92 624.92 624.92
20 669.40 0.235 0.435 0.29 RA 3 0 6 669.40 669.40 669.40 669.40
21 384.74 0.274 0.506 0.343 R-pDD/nOs 2 1 4 384.74 384.74 384.74 384.74
22 509.28 0.221 0.537 0.249 RA 2 2 7 509.28 509.28 509.28 509.28
23 375.85 0.140 0.356 0.151 RA 2 0 4 375.85 375.85 375.85 375.85
24 453.34 0.196 0.360 0.299 RA 0 2 5 453.34 453.34 453.34 453.34
25 845.97 0.259 0.463 0.248 RA 3 0 4 845.97 845.97 845.97 845.97
26 480.42 0.174 0.457 0.174 A 3 4 6 480.42 480.42 480.42 480.42
27 660.94 0.199 0.503 0.196 RA 3 2 5 660.94 660.94 660.94 660.94
28 800.84 0.443 0.539 0.426 R-pDD 5 0 nA 800.84 800.84 800.84
29 954.28 0.278 0.529 0.228 R-pDD 3 1 8 954.28 954.28 954.28 954.28
Mean 824.97 782.35 870.64 868.46 821.75 805.49 832.73 754.67 861.98
sD 376.09 267.12 472.71 548.78 374.94 311.97 520.38 267.13 424.44
p = 0.5373 p = 0.8690 p = 0.8682 p = 0.4752
hgF concentration of autistic children with gI disease, with (bold) and without Lnh, with (bold) and without erythema, with (bold) and without severe total 
gI disease, and with (bold) and without auto-antibodies (AncA and/or AscA), are compared. Diagnosis of autistic children with gI disease  (A-autistic; 
rA-autistic with regressive onset; PDD-pervasive developmental disorder; UD-undetermined; AsP-aspergers), severity of lymphonodular hyperplasia 
(Lnh), presence and severity of erythema, total gI disease severity, as well as the presence of auto-antibodies (AutoAb) are posted. severity of gI disease 
was scored according to mild (1 point), moderate (2 points) and marked (3 points) disease in each area (upper and lower gI) and for scope (macroscopic) 
and histology of each area. Therefore the maximum score for gI disease would be 12 (3 points each for upper scope, upper histology, lower scope and 
lower histology). A point system was also developed for severity of lymphoid nodular hyperplasia (Lnh). Patients were scored according to mild (1 point), 
moderate (2 points) and marked (3 points) LNH in each area (upper and lower GI) for a maximum of 6 points. And finally, a point system was also 
developed for severity of erythema. Patients were scored according to mild (1 point), moderate (2 points) and marked (3 points) erythema in each area 
(upper and lower gI) for a maximum of 6 points. russo et al
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Table 2. Significant difference between HGF in autistic with Gl disease and controls.
A GI A no GI A GI nA no GI A GI n AGI
Mean 824.97 1798.23 824.97 2544.65 824.97 1678.37
sD 376.09 1260.76 376.09 1063.49 376.09 694.42
seM 69.84 380.13 69.84 320.65 69.84 231.47
count (n) 29 11 29 11 29 9
  p = 0.0005 p = 0.0001 p = 0.001
Significant difference between HGF concentration (pg/ml) of 29 autistic children with chronic digestive disease (most with ileo-colonic lymphoid nodular 
hyperplasia (LNH) and inflammation of the colorectum, small bowel and/or stomach) (A GI), and 30 controls (11 age matched autistic children with no GI 
disease (A no gI), 11 age matched non autistic children without gI disease (nA no gI) and 9 age matched non autistic children with gI disease (nA gI)).
Table 3. hgF in autistic vs. controls.
Autistic non autistic
Mean 1092.619 2154.822
sD 838.3401 996.903
seM 132.5532 222.9143
n 40 20
p  0.0001
Significant difference between HGF concentration (pg/ml) of 40 autistic 
children  (with  and  without  gI  disease)  and  20  age  matched  controls 
(with and without gI disease).  
which would increase the frequency of DNA breakage. 
Thus, less c-MET could mean less control of inflam-
mation (i.e. more chronic inflammation), more reac-
tive oxygen species, more caspase-mediated damage 
and more uracil misincorporation.
The neurobiological basis for autism remains poorly 
understood. Other growth factors, such as transform-
ing growth factor-β163 and Epidermal Growth Factor64 
have been found to be deficient in autistic patients. 
Our results show that a significant number of autistic 
children with severe GI disease have lower concentra-
tion of serum HGF when compared to controls, and 
suggests  a  relationship  between  lower  HGF  levels 
and GI disease symptoms.
Although hypothetical, deficiency in either HGF 
or  c-MET  could  initiate  and  promote  a  sustained 
immune response consistent with chronic features of 
autism pathophysiology, and could therefore be an 
important contributor to the autism phenotype.
Increased  risk  for  autism,  due  to  a  functional 
polymorphism in the MET gene, and lower levels of 
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unbound HGF, may impart, particularly in individuals 
with severe GI disease, shared etiology of a parallel, 
although  independent,  disruption  of  brain  and 
peripheral organ development and function. Continued 
investigations of clinical populations will be needed 
to determine the contribution of lower concentrations 
of HGF to the etiology of the complex phenotype of 
autism.
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